Pembrolizumab for Fallopian Tube Cancer
This study is evaluating whether a combination of chemotherapy and immunotherapy might be a better treatment for ovarian cancer.
See full descriptionAbout the trial for Fallopian Tube Cancer
Treatment Groups
This trial involves 2 different treatments. Pembrolizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for female patients aged 18 and older. You must have received 1 prior treatment for Fallopian Tube Cancer or one of the other 5 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Pembrolizumab will improve 1 primary outcome and 5 secondary outcomes in patients with Fallopian Tube Cancer. Measurement will happen over the course of 24 weeks.
Who is running the study
Principal InvestigatorPatient Q & A Section
How many people get fallopian tube cancer a year in the United States?
Overall, [Fallopian tube cancer incidence rates were higher than expected] and the number of Fallopian tube cancer cases was higher than reported previously and the percentage of cases attributable to known risk factors was much lower. Although the exact number of Fallopian tube cancer cases in women is uncertain, estimates range from 25,000 to 50,000 annually in the United States. The proportion of Fallopian tube cancer cases attributable to known risk factors is estimated to be less than 50% (range, 34-66%). Results from a recent paper underscore the importance of surveillance and surveillance, including the use of new, rapid, and inexpensive approaches, for addressing this disease.
Can fallopian tube cancer be cured?
Fallopian tube cancer cannot be cured and its disease-free survival is extremely short. Survival of fallopian tube cancer in the United States is less than 10% at 5 years.
What are common treatments for fallopian tube cancer?
Treatment for fallopian tube cancer is highly individualized and depends on a variety of factors. In the majority of patients with cancer of the fallopian tube, surgery and/or radiation therapy are used. As of 2007, adjunctive surgery should be considered an option.
What causes fallopian tube cancer?
Fallopian tube cancer has a number of risk factors which are mostly unknown or only poorly understood. They include smoking, age, overweight and not observing the correct method of contraception. While the cancer occurs it often does not lead to death or infertility, but it does impede the ability of the person to become pregnant. More research is needed to clarify these factors.
What are the signs of fallopian tube cancer?
Signs of fallopian-tube cancer may include a mass felt as enlarged breasts or as deep, unilateral pain in the abdomen or pelvis. The most common sign of malignancy is infertility. Most women are diagnosed after they have consulted other physicians. In these women, treatment is often delayed and the chance of cure low. It is imperative that women be familiar with their signs so prompt referral is possible.
What is fallopian tube cancer?
Fallopian tube cancer is the most common form of gynecological cancer occurring in elderly women in the United States. More than a quarter of women diagnosed with advanced stage disease die of the disease.
Is pembrolizumab safe for people?
Pembrolizumab was well tolerated in this series of patients with non-metastatic germ cell tumors. Median TTP and PFI times were not significantly longer in the pembrolizumab-treated group than in the chemotherapy-alone group.
How serious can fallopian tube cancer be?
Fallopian tube cancer can be deadly. It is important for patients and their oncologists to remember that though the disease is uncommon, it has a very high mortality rate. In order to reduce this risk, it is critical that patients receive treatment plans with specific goals. If you have not received treatment plans for fallopian tube cancer before, it is essential to do so now. Please use the power site to explore treatment options for fallopian tube cancer.
Does pembrolizumab improve quality of life for those with fallopian tube cancer?
This research demonstrates that pembrolizumab enhances quality of life over placebo in the management of fallopian tube cancer and reduces treatment-related fatigue. Because a cure for fallopian tube cancer does not yet exist and many women receive pembrolizumab, more research is needed to fully understand the effects of pembrolizumab on quality of life.
What is the survival rate for fallopian tube cancer?
The long-term survival of fallopian tube cancer is more than 80%, but is not yet adequate after the first year. More attention should be paid to the early detection and complete treatment of fallopian tube cancer.
What is pembrolizumab?
The combination of pembrolizumab with lapatinib is active in treating selected patients with [primary or [secondary]] stage III serous Ovarian cancer. The addition of pembrolizumab to lapatinib significantly improved PFS versus lapatinib alone, which suggests that (1) the pembrolizumab may be effective in treating serous Ovarian cancer, and (2) the lapatinib may be used effectively in the first line versus second line, and with the pembrolizumab in addition.
What are the common side effects of pembrolizumab?
The most frequent (in >75% of cases) CIs observed with pembrolizumab are nausea, fatigue, vomiting, fever/chills and constipation/diarrhoea. Rare (in <5% of cases) CIs include headache, hypotension, myalgia, arthralgia, rash, arthrosis, dry eyes/saliva and urticaria. In a study to evaluate CIs secondary to pembrolizumab in adult patients with cancer and non-resectable solid tumors, 10% of these events were thought to be caused by medication.